CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets

Cited by (816)

Items 301–400 of 816

1. Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones
   Richard H. Smith, Yun-Ching Chen, Fayaz Seifuddin, Daniel N. Hupalo, Camille Alba, Robert N. Reger, Xin Tian, Daisuke Araki, Clifton L. Dalgard, Richard W. Childs et al. · 2020 · Genes
2. A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa
   Thomas Köcher, Johannes Bischof, Simone Alexandra Haas, Oliver Patrick March, Bernadette Liemberger, Stefan Hainzl, Julia Illmer, Anna Hoog, Katharina Muigg, Heide‐Marie Binder et al. · 2021 · Molecular Therapy — Nucleic Acids
3. Prime editing: current advances and therapeutic opportunities in human diseases
   Yidian Fu, Xiaoyu He, Xin D. Gao, Fang Li, Shengfang Ge, Zhi Hua Yang, Xianqun Fan · 2023 · 中国科学通报：英文版
4. Perspectives on the basic and applied aspects of crassulacean acid metabolism (CAM) research
   Degao Liu, Kaitlin J. Palla, Rongbin Hu, Robert C. Moseley, Christopher Mendoza, Mei Chen, Paul E. Abraham, Jessy Labbé, Udaya C. Kalluri, Timothy James Tschaplinski et al. · 2018 · Plant Science
5. Progress in the application of CRISPR: From gene to base editing
   Wenyi Wu, Yanhui Yang, Hetian Lei · 2018 · Medicinal Research Reviews
6. Engineering guide RNA to reduce the off-target effects of CRISPR
   Jing Wu, Hao Yin · 2019 · Journal of genetics and genomics/Journal of Genetics and Genomics
7. When genome editing goes off-target
   Hannah R. Kempton, Lei S. Qi · 2019 · Science
8. CRISPR Cautions: Biosecurity Implications of Gene Editing
   Rachel M. West, Gigi Kwik Grönvall · 2020 · Perspectives in biology and medicine
9. Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease
   Kathleen A. Christie, Louise J. Robertson, Caroline Conway, Kevin Blighe, Larry DeDionisio, Connie Chao-Shern, Amanda M. Kowalczyk, John Marshall, Douglass M. Turnbull, M. Andrew Nesbit et al. · 2020 · Molecular Therapy
10. Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
    Jackson M. J. Oultram, Joseph L. Pegler, Tim A. Bowser, Luke John Ney, Andrew Leigh Eamens, Christopher P. L. Grof · 2021 · Biomedicines
11. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
    Laura Torella, Julia Klermund, Martin Bilbao‐Arribas, Ibón Tamayo, Geoffroy Andrieux, Kay Ole Chmielewski, África Vales, Cristina Olagüe, Daniel Moreno, Ivan Raimondi et al. · 2024 · EMBO Molecular Medicine
12. A positive, growth-based PAM screen identifies noncanonical motifs recognized by the S. pyogenes Cas9
    Daphne Collias, Ryan T. Leenay, Rebecca Slotkowski, Zhicheng Zuo, Scott P. Collins, B. A. McGirr, Jin Liu, Chase L. Beisel · 2020 · Science Advances
13. Targeting Specificity of the CRISPR/Cas9 System
    Ipek Tasan, Huimin Zhao · 2017 · ACS Synthetic Biology
14. Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice
    Chang Long Li, Aphrodite Georgakopoulou, Kiriaki Paschoudi, Anna Kate Anderson, Lishan Huang, Sucheol Gil, Maria Giannaki, Efthymia Vlachaki, Gregory A. Newby, David R. Liu et al. · 2024 · Molecular Therapy
15. CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders
    Júlia-Jié Cabré-Romans, Raquel Cuella-Martin · 2025 · Frontiers in Genome Editing
16. Human-specific gene expansions contribute to brain evolution
    2025
17. CRISPR for Neuromuscular Disorders: Gene Editing and Beyond
    Courtney S. Young, April D. Pyle, Melissa J. Spencer · 2019 · Physiology
18. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR–Cas9 variants
    Karthik Murugan, Shravanti Krishna Suresh, Arun Somwarpet Seetharam, Andrew Josef Severin, Dipali G. Sashital · 2021 · Nucleic Acids Research
19. PEAC-seq adopts Prime Editor to detect CRISPR off-target and DNA translocation
    Zhenxing Yu, Zhike Lu, Jingjing Li, Yingying Wang, Panfeng Wu, Yini Li, Yangfan Zhou, Bailun Li, Heng Zhang, Yingzheng Liu et al. · 2022 · Nature Communications
20. Transformer-based anti-noise models for CRISPR-Cas9 off-target activities prediction
    Zengrui Guan, Zhenran Jiang · 2023 · Briefings in Bioinformatics
21. Interpretable neural architecture search and transfer learning for understanding CRISPR–Cas9 off-target enzymatic reactions
    Zijun Zhang, Adam Lamson, Michael Shelley, Olga G. Troyanskaya · 2023 · Nature Computational Science
22. Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
    Xiaofeng Dai, Pilar Blancafort, Peiyu Wang, Agustin Sgro, Erik W. Thompson, Kostya Ostrikov · 2020 · Advanced Science
23. Extru-seq: A method for predicting genome-wide Cas9 off-target sites with advantages of both cell-based and in vitro approaches
    Kwon, Jeonghun, Kim, Minyoung, Hwang, Woochang, Jo, Anna, Hwang, Gue-Ho, Jung, Minhee, Kim, Un Gi, Cui, Gang, Kim, Heonseok, Eom, Joon-Ho et al. · 2023 · Genome biology
24. Robust CRISPR/Cas9 Genome Editing of the HUDEP-2 Erythroid Precursor Line Using Plasmids and Single-Stranded Oligonucleotide Donors
    Gemma Moir-Meyer, Pak Leng Cheong, Aude-Anaïs Olijnik, Jill M. Brown, Samantha J.L. Knight, Andrew John King, Ryo Kurita, Yukio Nakamura, Richard J. Gibbons, Douglas R. Higgs et al. · 2018 · Methods and Protocols
25. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
    Catherine M. Baker, Matthew S. Hayden · 2020 · F1000Research
26. The CRISPR revolution and its potential impact on global health security
    Kyle E. Watters, Jesse Kirkpatrick, Megan Joan Palmer, Gregory D. Koblentz · 2021 · Pathogens and Global Health
27. High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells
    Daniel G. Allen, Lucien E. Weiss, Alon Saguy, Michael Rosenberg, Ortal Iancu, Omri Matalon, Ciaran M. Lee, Katia Beider, Arnon Nagler, Yoav Shechtman et al. · 2022 · The CRISPR Journal
28. Modelling urea cycle disorders using iPSCs
    Claire E. Duff, Julien Baruteau · 2022 · npj Regenerative Medicine
29. Massively parallel CRISPR off-target detection enables rapid off-target prediction model building
    Rui Tian, Chen Cao, Dan He, Dirong Dong, Lili Sun, Jiashuo Liu, Ye Chen, Yuyan Wang, Zheying Huang, Lifang Li et al. · 2023 · Med
30. Whole genome analysis for 163 gRNAs in Cas9-edited mice reveals minimal off-target activity
    Kevin A. Peterson, Sam Khalouei, Nour Hanafi, Joshua A. Wood, Denise Grant Lanza, Lauri G. Lintott, Brandon Willis, John R. Seavitt, Robert E. Braun, Mary E. Dickinson et al. · 2023 · Communications Biology
31. Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break
    Geoffrey L. Rogers, Hsu-Yu Chen, Heidy Morales, Paula M. Cannon · 2019 · Molecular Therapy
32. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
    Pandey, Manish, Ojha, Divya, Bansal, Sakshi, Rode, Ambadas B., Chawla, Geetanjali · 2021 · Molecular Aspects of Medicine
33. Assessment of Autism Zebrafish Mutant Models Using a High-Throughput Larval Phenotyping Platform
    Alexandra Colón-Rodríguez, José M. Uribe‐Salazar, KaeChandra Weyenberg, Aditya Sriram, Alejandra Quezada, Gulhan Kaya, Emily Jao, Brittany Radke, Pamela J. Lein, Megan Y. Dennis · 2020 · Frontiers in Cell and Developmental Biology
34. Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques
    Aisha A. Aljanahi, Cícera Regina Lazzarotto, Shirley Chen, Tae–Hoon Shin, Stefan Cordes, Xing Fan, Isabel Jabara, Yifan Zhou, David J. Young, Byung‐Chul Lee et al. · 2021 · Molecular Therapy
35. CRISPR-derived genome editing therapies: Progress from bench to bedside
    Holly A. Rees, Alex C. Minella, Cameron A. Burnett, Alexis C. Komor, Nicole M. Gaudelli · 2021 · Molecular Therapy
36. Progress and Prospects of Gene Editing in Pluripotent Stem Cells
    Zhenwu Zhang, Xinyu Bao, Chao‐Po Lin · 2023 · Biomedicines
37. Generating, modeling and evaluating a large-scale set of CRISPR/Cas9 off-target sites with bulges
    Ofir Yaish, Yaron Orenstein · 2024 · Nucleic Acids Research
38. The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
    Caroline F. Peddle, Robert Edward MacLaren · 2017 · PubMed Central
39. Evaluation of off-targets predicted by sgRNA design tools
    Jaspreet Kaur Dhanjal, Samvit Dammalapati, Shreya Pal, Durai Sundar · 2020 · Genomics
40. Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On‐ and Off‐Target Damage
    Anthony Newman, Lora M. Starrs, Gaétan Burgio · 2020 · BioEssays
41. Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
    Karl Petri, Elvira D’Ippolito, Annette Künkele, Ulrike Koehl, Dirk Hans Busch, Hermann Einsele, Michael Hudecek · 2025 · Nature Reviews Clinical Oncology
42. p53: from understanding its structure to advances in therapeutic targeting
    Wenhua Wang, Xia Liu, Hengqi Liu, Hassan Abolhassani, Han Yan, Huilai Zhang, Xianhuo Wang · 2026 · Signal Transduction and Targeted Therapy
43. CRISPR-gRNA Design
    Maria Pallarès-Masmitjà, Nastassia Knödlseder, Marc Güell · 2019 · Methods in molecular biology
44. An unbiased method for evaluating the genome-wide specificity of base editors in rice
    Shuai Jin, Qiang Gao, Caixia Gao · 2020 · Nature Protocols
45. Genome-wide specificity of plant genome editing by both CRISPR–Cas9 and TALEN
    Nadia Bessoltane, Florence Charlot, Anouchka Guyon‐Debast, Delphine Charif, Kostlend Mara, Cécile Collonnier, Pierre‐François Perroud, Mark Tepfer, Fabien Nogué · 2022 · Scientific Reports
46. CRISPR‐Cas9: A cornerstone for the evolution of precision medicine
    Sleiman Razzouk · 2018 · Annals of Human Genetics
47. Learning to quantify uncertainty in off-target activity for CRISPR guide RNAs
    Özden, Furkan, Minary, Peter · 2024 · Nucleic Acids Research
48. BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
    Selami Demirci, Jing Zeng, Rahul Palchaudhuri, Chuanfeng Wu, Diana M. Abraham, Taha Bartu Hayal, Khaled Essawi, My Anh Nguyen, Ulana Stasula, Rebecca Chu et al. · 2024 · Cell stem cell
49. Position of Deltaproteobacteria Cas12e nuclease cleavage sites depends on spacer length of guide RNA
    Polina Selkova, Aleksandra Vasileva, Georgii E. Pobegalov, Olga S. Musharova, Anatolii Arseniev, Maksim Kazalov, Tatyana Zyubko, Nataliia Shcheglova, Tatyana Artamonova, Mikhail A. Khodorkovskii et al. · 2020 · RNA Biology
50. piCRISPR: Physically informed deep learning models for CRISPR/Cas9 off-target cleavage prediction
    Florian Störtz, Jeffrey Kelvin Mak, Péter Mináry · 2023 · Artificial Intelligence in the Life Sciences
51. A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa
    Gernot Neumayer, Jessica L. Torkelson, Shengdi Li, Kelly McCarthy, Hanson Hui Zhen, Madhuri Vangipuram, Marius Marc-Daniel Mader, Gulilat Gebeyehu, Taysir M. Jaouni, J. Jackow et al. · 2024 · Nature Communications
52. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo
    Xuejiao Piao, Dawei Meng, Xue Zhang, Qiang Song, Hailong Lv, Yichang Jia · 2022 · Scientific Reports
53. In vivo photoreceptor base editing ameliorates rhodopsin-E150K autosomal-recessive retinitis pigmentosa in mice
    Du, Samuel W., Newby, Gregory A., Salom, David, Gao, Fangyuan, Menezes, Carolline Rodrigues, Suh, Susie, Choi, Elliot H., Chen, Paul Z., Liu, David R., Palczewski, Krzysztof · 2024 · Proceedings of the National Academy of Sciences
54. Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
    James B. Papizan, Shaina N. Porter, Akshay Sharma, Shondra M. Pruett‐Miller · 2020 · Journal of Biomedical Research
55. Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells
    Myriam Lemmens, Benoit Fischer, Michael Zogg, Lindsey Ulkus Rodrigues, Gráinne Kerr, Alberto Del Río-Espínola, Fanny Schaeffer, Danilo Maddalo, Valérie Dubost, Alessandro Piaia et al. · 2021 · Molecular Therapy — Methods & Clinical Development
56. Challenges of Gene Editing Therapies for Genodermatoses
    I. Brooks, A. Sheriff, Declan Moran, Jing-Bo Wang, J. Jacków · 2023 · International Journal of Molecular Sciences
57. Prediction of CRISPR-Cas9 off-target activities with mismatches and indels based on hybrid neural network
    Yanpeng Yang, Jian Li, Quan Zou, Yaoping Ruan, Hailin Feng · 2023 · Computational and Structural Biotechnology Journal
58. CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy
    Mingming Qin, Chunhao Deng, Liewei Wen, Guoqun Luo, Ya Meng · 2024 · Journal of Translational Medicine
59. Quantifying CRISPR off-target effects
    Soragia Athina Gkazi · 2019 · Emerging Topics in Life Sciences
60. Identification of Guide-Intrinsic Determinants of Cas9 Specificity
    Nicholas C. Huston, Josh Tycko, Eric L. Tillotson, Christopher J. Wilson, Vic E. Myer, Hariharan Jayaram, Barrett E. Steinberg · 2019 · The CRISPR Journal
61. A systematic evaluation of data processing and problem formulation of CRISPR off-target site prediction
    Yaish, Ofir, Asif, Maor, Orenstein, Yaron · 2022 · Briefings in Bioinformatics
62. Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology
    A Vipin Menon, Bicna Song, Lumen Chao, Diksha Sriram, Pamela A. Chansky, Ishnoor Bakshi, Jane Ulianova, Wei Li · 2025 · Frontiers in Genome Editing
63. Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE
    Cícera Regina Lazzarotto, Varun Katta, Yichao Li, Garret Manquen, Rachael K. Wood, Jacqueline Chyr, Elizabeth Urbina, Azusa Matsubara, GaHyun Lee, Xiaolin Wu et al. · 2026 · Nature Biotechnology
64. Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications
    Wei Sheng Siew, Yin-Quan Tang, Chee Kei Kong, Bey Hing Goh, Serena Zacchigna, Kamal Dua, Dinesh Kumar Chellappan, Acharaporn Duangjai, Surasak Saokaew, Pochamana Phisalprapa et al. · 2021 · International Journal of Molecular Sciences
65. Methods for the directed evolution of biomolecular interactions
    Victoria Cochran Xie, Matthew J. Styles, Bryan C. Dickinson · 2022 · Trends in Biochemical Sciences
66. Breaking Yield Ceiling in Wheat: Progress and Future Prospects
    Neeraj Pal, Dinesh Kumar Saini, Sundip Kumar · 2022 · IntechOpen eBooks
67. Genome editing in cancer: Challenges and potential opportunities
    Dor Breier, Dan Peer · 2022 · Bioactive Materials
68. Multiplexed engineering and precision gene editing in cellular immunotherapy
    Alexander Biederstädt, Gohar Shahwar Manzar, May Daher · 2022 · Frontiers in Immunology
69. The application of CRISPR/Cas9–based genome-wide screening to disease research
    Xiuqin Chen, Min Zheng, Su Lin, Meiqing Huang, Shaoying Chen, Shilong Chen · 2024 · Molecular and Cellular Probes
70. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection
    Abdullah Ely, Prashika Singh, Tiffany S. Smith, Patrick B. Arbuthnot · 2020 · Advanced Drug Delivery Reviews
71. Genome-wide detection and analysis of CRISPR-Cas off-targets
    Tomás Rodríguez, Sina Dadafarin, Henry Pratt, Pengpeng Liu, Nadia Amrani, Lihua Julie Zhu · 2021 · Progress in molecular biology and translational science
72. CRISPR genome engineering for retinal diseases
    Ariel Kantor, Michelle E. McClements, Caroline F. Peddle, Lewis E. Fry, Ahmed Salman, Jasmina Cehajic‐Kapetanovic, Kanmin Xue, Robert Edward MacLaren · 2021 · Progress in molecular biology and translational science
73. CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects
    Han Han, Xiaoyan Sun, Xiaoyun Guo, Jiaxin Wen, Xiaoming Zhao, Weiqiang Zhou · 2025 · Frontiers in Pharmacology
74. Characterizing off-target effects of genome editors
    Xichen Rao, Huanan Zhao, Chuyun Shao, Chengqi Yi · 2023 · Current Opinion in Biomedical Engineering
75. Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
    Sun‐Young Lee, Tae‐Don Kim · 2023 · International Journal of Molecular Sciences
76. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development
    Katelyn Millette, Senta K Georgia · 2017 · Current Diabetes Reports
77. CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases
    Justin S. Antony, A.K.M. Ashiqul Haque, Andrés Lamsfus‐Calle, Alberto Daniel-Moreno, Markus Mezger, Michael Kormann · 2018 · Advances in Cell and Gene Therapy
78. CRISPR to the Rescue: Advances in Gene Editing for the FMR1 Gene
    Carolyn M. Yrigollen, Beverly L. Davidson · 2019 · Brain Sciences
79. Novel miR-29b target regulation patterns are revealed in two different cell lines
    Wenting Zhao, Lesley Cheng, Camelia Y. J. Quek, Shayne A. Bellingham, Andrew Francis Hill · 2019 · Scientific Reports
80. Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites
    Cheng-Han Chung, Alexander G. Allen, Andrew Atkins, Neil T. Sullivan, Greg Homan, Robert Costello, Rebekah Madrid, Michael R. Nonnemacher, Will Dampier, Brian L. Wigdahl · 2020 · Molecular Therapy — Nucleic Acids
81. The development of genome editing tools as powerful techniques with versatile applications in biotechnology and medicine: CRISPR/Cas9, ZnF and TALE nucleases, RNA interference, and Cre/loxP
    Sabrina Schulze, Michael Lammers · 2020 · ChemTexts
82. Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I
    Peng Gu, Qin Zhao Yang, Bangzhu Chen, Yanan Bie, Wen Liu, Yu-Guang Tian, Hongquan Luo, Tao Xu, Chunjin Liang, Xing Ye et al. · 2021 · Molecular Therapy — Methods & Clinical Development
83. In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
    Chiara Simoni, Elena Barbon, Andrés Fernando Muro, Alessio Cantore · 2024 · Frontiers in Genome Editing
84. Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors
    Kshitiz Singh, Raffaele Fronza, Hanneke Evens, Marinee Chuah, Thierry VandenDriessche · 2024 · Molecular Therapy — Methods & Clinical Development
85. Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications
    Yueying Huang, Xiaoyu Zhang, Ping Zhu, Ling Ji · 2022 · World Journal of Clinical Cases
86. Cytosine Deaminase Base Editing to Restore COL7A1 in Dystrophic Epidermolysis Bullosa Human: Murine Skin Model
    Gaetano Naso, Soragia Athina Gkazi, Christos Georgiadis, Vignesh Jayarajan, J. Jackow, Roland A. Fleck, Leanne Allison, Olumide Kayode Ogunbiyi, John Alexander McGrath, Duško Ilić et al. · 2023 · JID Innovations
87. Hybrid multitask learning reveals sequence features driving specificity in the CRISPR/Cas9 system
    Vora, Dhvani Sandip, Yadav, Shashank, Sundar, Durai · 2023 · Biomolecules
88. Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders
    Daniel G. Allen, Nechama Kalter, Michael Rosenberg, Ayal Hendel · 2023 · Pharmaceutics
89. In silico Method in CRISPR/Cas System: An Expedite and Powerful Booster
    Yuwei Zhang, Guofang Zhao, Fatma Yislam Hadi Ahmed, Tianfei Yi, Shiyun Hu, Ting Cai, Qi Liao · 2020 · Frontiers in Oncology
90. CRISPR, animals, and FDA oversight: Building a path to success
    Laura R. Epstein, Stella S. Lee, Mayumi F. Miller, Heather A. Lombardi · 2021 · Proceedings of the National Academy of Sciences
91. Perfecting Targeting in CRISPR
    Hainan Zhang, Tong Li, Yidi Sun, Hui Yang · 2021 · Annual Review of Genetics
92. Fast and inexpensive whole-genome sequencing library preparation from intact yeast cells
    Sibylle Chantal Vonesch, Shengdi Li, Chelsea Szu‐Tu, Bianca P. Hennig, Nikolay Dobrev, and Lars M Steinmetz · 2020 · G3 Genes Genomes Genetics
93. Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
    Maria Carmina Castiello, Samuele Ferrari, ANNA MARIA VILLA · 2023 · Seminars in Immunology
94. CRISPR/Cas9 as a Mutagenic Factor
    Andrey R. Shumega, Youri I. Pavlov, Angelina V. Chirinskaite, Aleksandr A. Rubel, Sergey Georgievich Inge-Vechtomov, Elena Igorevna Stepchenkova · 2024 · International Journal of Molecular Sciences
95. An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation
    Immacolata Porreca, Robert A. Blassberg, Jennifer A. Harbottle, Bronwyn C. Joubert, Olga Mielczarek, Jesse Stombaugh, Kevin Hemphill, Jonathan Sumner, Deividas Pazeraitis, Julia Liz Touza et al. · 2024 · Molecular Therapy
96. Crispr-SGRU: Prediction of CRISPR/Cas9 Off-Target Activities with Mismatches and Indels Using Stacked BiGRU
    Guishan Zhang, Ye Luo, Huanzeng Xie, Zhiming Dai · 2024 · International Journal of Molecular Sciences
97. Solid-State Nanopore Real-Time Assay for Monitoring Cas9 Endonuclease Reactivity
    Chalmers Chi Cheng Chau, Nicole E. Weckman, Emma E. Thomson, Paolo Actis · 2025 · ACS Nano
98. Diminished adherence of Biomphalaria glabrata embryonic cell line to sporocysts of Schistosoma mansoni following programmed knockout of the allograft inflammatory factor
    Fernanda Sales Coelho, Rutchanee Rodpai, André Miller, Shannon E. Karinshak, Victoria H. Mann, Omar dos Santos Carvalho, Roberta Lima Caldeira, Marina de Moraes Mourão, Paul J. Brindley, Wannaporn Ittiprasert · 2020 · Parasites & Vectors
99. CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease
    Erin R. Burnight, Laura R. Bohrer, Joseph C. Giacalone, Darcey Klaahsen, Heather T. Daggett, Jade S. East, Robert A Madumba, Kristan S. Worthington, Robert F. Mullins, Edwin M. Stone et al. · 2018 · The CRISPR Journal
100. Hemophilia as a blueprint for gene therapy
     Margaret V. Ragni · 2021 · Science